Replies to post #172657 on Biotech Values

[mcbio]

RNA

1. While their PR yesterday said that they regained the rights to disapersen, I think that the FierceBiotech headline more accurately captures the reality of the situation: "GSK dumps a failed muscular dystrophy drug back in Prosensa's lap."

Yes, I think that's fair.

Since their pipeline is far from empty, why not simply admit that disapersen didn't work out, and move on?

Because perhaps there's no definitive answer on that front yet? Again, the Phase 2 data was very strong and there are at least some reasons to believe that GSK simply screwed up the Phase 3 trial design (and not that drisa doesn't work). Obviously the odds are long given that GSK walked but I read today that RNA isn't yet finished analyzing the Phase 3 data.

[jq1234]

In this particular case, if you don't think Drisapersen even works at least for some patients, there really isn't much reason besides EU patent to hold RNA as rest of their pipelines use similar approaches.